Results 101 to 110 of about 54,019 (242)

Incident mental health episodes after initiation of gabapentinoids vs. dopamine agonists for early-onset idiopathic restless legs syndrome. [PDF]

Psychiatry Res, 2023
Costales B, Vouri SM, Brown JD, Setlow B, Goodin AJ.   +4 more
europepmc   +1 more source

Transcranial Pulse Stimulation Enhances Dexterity in Parkinson's Disease: A Randomized Sham‐Controlled Trial

Movement Disorders, EarlyView.
Abstract Background Ultrasound‐based neuromodulation, capable of reaching deep brain areas with high precision, represents cutting‐edge technology in non‐invasive brain stimulation and is investigated as a novel treatment for neurological and psychiatric disorders, including Parkinson's disease (PD).
Eva Matt, Nina Plischek, Michael Mitterwallner, Sonja Radjenovic, Alexandra Weber, Alina Domitner, Gregor Dörl, Anna Zettl, Sarah Osou, Anna Leitgeb, Agnes Santer, Viktoria Winkler, Julia Mandelburger, Heidemarie Zach, Roland Beisteiner   +14 more
wiley   +1 more source

Observations on an Open‐Label Phase 1/2 Dopamine Gene Therapy Trial (OXB‐102/Axo‐Lenti‐PD) in People with Parkinson's Disease

Movement Disorders, EarlyView.
Abstract Background SUNRISE‐PD was a dose‐escalating, phase 1/2 study investigating a second‐generation lentiviral vector gene therapy delivering the genes for dopamine synthesis (OXB‐102) to treat Parkinson's disease (PD). The trial was prematurely terminated due to insolvency of the sponsor.
Simon Rowe, Amy Evans, Saeed Kayhanian, Philip C. Buttery, Robert Morris, Katie Andresen, Laura Sherlock, Samuel Hewitt, Tagore Nakornchai, Marwan Hariz, Kyriacos Mitrophanous, Ludvic Zrinzo, Matthew Appleby, Phil Woodgate, Seema Maru, Patricia Limousin, Christine Girges, Thomas Foltynie, Stephane Palfi, Roger A. Barker   +19 more
wiley   +1 more source

Incidental Resolution of Dopamine Agonist Induced Impulse Control Disorder with GLP‐1 Receptor Agonist

Movement Disorders Clinical Practice, EarlyView.
Hannah Kelly, Thomas Davis
wiley   +1 more source

Challenges of Pain in Parkinson's Disease: Results from the OCEAN Study

Movement Disorders, EarlyView.
Abstract Background Pain is a common non‐motor symptom in Parkinson’s disease (PD) and is often associated to fluctuations. Objective The OpiCapone Effect on motor fluctuations and pAiN (OCEAN) study evaluated the effect of opicapone on fluctuation‐related pain when added to levodopa therapy in PD patients.
Kallol Ray Chaudhuri, Joaquim J. Ferreira, Angelo Antonini, Olivier Rascol, Monica M. Kurtis, Alexander Storch, José‐Francisco Rocha, Raquel Costa, Diogo Magalhães, Guillermo Castilla‐Fernández, Helena C. Brigas, Joerg Holenz, Per Odin, on behalf of the OCEAN study group   +13 more
wiley   +1 more source

Resistance to Dopamine Agonists in Pituitary Tumors: Molecular Mechanisms. [PDF]

Front Endocrinol (Lausanne), 2021
Pivonello C, Patalano R, Negri M, Pirchio R, Colao A, Pivonello R, Auriemma RS.   +6 more
europepmc   +1 more source

Plasma p‐tau217 Versus p‐tau181 in Parkinson's Disease: Differential Associations with Alzheimer's Disease‐Related Neurostructural Changes and Cognitive Function

Movement Disorders, EarlyView.
Abstract Background Plasma phosphorylated‐tau at threonine‐217 (p‐tau217) and threonine‐181 (p‐tau181) are scalable, minimally invasive biomarkers of Alzheimer's disease (AD) pathology. In Parkinson's disease (PD), AD co‐pathology may contribute to its clinical heterogeneity.
Eleonora Fiorenzato, Simone Cauzzo, Giulia Musso, Roberta Biundo, Chiara Ceolin, Chiara Cosma, Carmelo Alessandro Fogliano, Wassilios G. Meissner, Valentina Misenti, Stefania Moz, Maria Laura Nasi, Francesca Vianello, Renzo Manara, Martina Montagnana, Giuseppe Sergi, Angelo Antonini, on behalf of the OPA Working Group   +16 more
wiley   +1 more source

Dopamine agonists for preventing ovarian hyperstimulation syndrome. [PDF]

Cochrane Database Syst Rev, 2021
Tang H, Mourad SM, Wang A, Zhai SD, Hart RJ.   +4 more
europepmc   +1 more source

Dopamine Agonists in the Management of Non-Functioning Pituitary Adenomas. [PDF]

Acta Endocrinol (Buchar), 2021
Capatina C, Poiana C.
europepmc   +1 more source

High‐Fat Diet Exacerbates Neuropathology in a Transgenic Mouse Model of Multiple System Atrophy

Movement Disorders, EarlyView.
Abstract Background Multiple system atrophy (MSA) is a rare and devastating neurodegenerative disorder. Accumulating clinical and preclinical evidence suggests that diabetes and insulin resistance may adversely influence MSA pathophysiology. Objective We investigated the potential association between diabetes, impaired glucose homeostasis, and MSA ...
Marie‐Laure Arotcarena, Anna Delamarre, Miguel Lopez‐Cuina, Hugo Martin, Elio Balpe, Xavier Fioramonti, Erwan Bezard, Wassilios G. Meissner   +7 more
wiley   +1 more source